Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 3/20 | 0.58 |
| ▸ | ANPEP | P15144 | 2/20 | 0.38 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.32 |
| ▸ | CHKA | P35790 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.30 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9175624 | 1.00 | FDPS (0.58) | FDPSANPEPERAP2MEN1KMT2A | |
| SCHEMBL9565325 | 0.98 | FDPS (0.60) | FDPSANPEPERAP2MEN1KMT2A | |
| SCHEMBL9601894 | 0.95 | FDPS (0.58) | FDPSANPEPERAP2MEN1KMT2A | |
| SCHEMBL12250790 | 0.84 | FDPS (0.50) | FDPSANPEPERAP2CA2CA12 | |
| SCHEMBL9601881 | 0.84 | FDPS (0.45) | FDPSANPEPERAP2CA2CA12 | |
| SCHEMBL3080928 | 0.80 | FDPS (0.75) | FDPSANPEPERAP2 | |
| SCHEMBL203348 | 0.80 | FDPS (0.75) | FDPSANPEPERAP2 | |
| SCHEMBL898693 | 0.80 | FDPS (0.75) | FDPSANPEPERAP2 | |
| SCHEMBL6668799 | 0.77 | FDPS (0.39) | FDPSANPEPERAP2 | |
| SCHEMBL2203676 | 0.75 | FDPS (0.85) | FDPSANPEPERAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7696331-B2 | High dose radionuclide complexes for bone marrow treatment | PONIARD PHARMACEUTICALS, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| US-7691985-B2 | Skeletal-targeted radiation to treat bone-associated pathologies | PONIARD PHARMACEUTICALS, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-7605239-B2 | Skeletal-targeted radiation to treat bone-associated pathologies | PONIARD PHARMACEUTICALS, INC. (US) | 2009-10-20 | — | — | US | disclosed |
| US-20090136419-A1 | HIGH DOSE RADIONUCLIDE COMPLEXES FOR BONE MARROW TREATMENT | PONIARD PHARMACEUTICALS, INC. | 2009-05-28 | — | — | US | disclosed |
| US-20080279773-A1 | SKELETAL-TARGETED RADIATION TO TREAT BONE-ASSOCIATED PATHOLOGIES | PONIARD PHARMACEUTICALS, INC. | 2008-11-13 | — | — | US | disclosed |
| US-7408046-B2 | Treatment of bone-associated cancers | PONIARD PHARMACEUTICALS, INC. (US) | 2008-08-05 | — | — | US | disclosed |
| US-7385042-B2 | Therapeutic and diagnostic compounds, compositions, and methods | PONIARD PHARMACEUTICALS, INC. (US) | 2008-06-10 | — | — | US | disclosed |
| US-7378077-B2 | High dose radionuclide complexes for bone marrow suppression | PONIARD PHARMACEUTICALS, INC. (US) | 2008-05-27 | — | — | US | disclosed |
| US-20070053833-A1 | High dose radionuclide complexes for bone marrow suppression | NEORX CORPORATION | 2007-03-08 | — | — | US | disclosed |
| US-20060251578-A1 | Structurally distinct radionuclide complexes of multinitrogen heterocycles having phosphonic acid groups that target bone, and thus, are useful as imaging and therapeutic agents (e.g., for bone marrow suppression, cancer, bone pain) | NEORX CORPORATION | 2006-11-09 | — | — | US | disclosed |
| EP-1390081-A2 | THERAPEUTIC AND DIAGNOSTIC COMPOUNDS, COMPOSITIONS, AND METHODS | NEORX CORPORATION (US) | 2004-02-25 | — | — | EP | disclosed |
| US-20020176818-A1 | High dose radionuclide complexes for bone marrow suppression | PONIARD PHARMACEUTICALS, INC. | 2002-11-28 | — | — | US | disclosed |
| WO-2002062398-A2 | RADIOACTIVELY LABELLED CONJUGATES OF PHOSPHONATES | NEORX CORPORATION (US) | 2002-08-15 | — | — | WO | disclosed |
| EP-1191948-A2 | HIGH DOSE RADIONUCLIDE COMPLEXES FOR BONE MARROW SUPPRESSION | NEORX CORPORATION (US) | 2002-04-03 | — | — | EP | disclosed |
| WO-2000076556-A9 | HIGH DOSE RADIONUCLIDE COMPLEXES FOR BONE MARROW SUPPRESSION | NEORX CORP (US) | 2001-11-08 | — | — | WO | disclosed |
| WO-2000076556-A2 | HIGH DOSE RADIONUCLIDE COMPLEXES FOR BONE MARROW SUPPRESSION | NEORX CORPORATION (US) | 2000-12-21 | — | — | WO | disclosed |
| US-5428155-A | PH controlled sulfomethylation of 1,4,7,10-tetraazacyclododecane; displacement with sodium cyanide; hydrolysis to symmetrical acetic acid side groups | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1995-06-27 | — | — | US | disclosed |
| EP-0618910-A1 | SYNTHESIS OF POLYAZAMACROCYCLES WITH MORE THAN ONE TYPE OF SIDE-CHAIN CHELATING GROUPS | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1994-10-12 | — | — | EP | disclosed |
| US-5316757-A | MRI contrast agent | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1994-05-31 | — | — | US | disclosed |
| WO-1993012097-A1 | SYNTHESIS OF POLYAZAMACROCYCLES WITH MORE THAN ONE TYPE OF SIDE-CHAIN CHELATING GROUPS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1993-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080279773-A1 | SKELETAL-TARGETED RADIATION TO TREAT BONE-ASSOCIATED PATHOLOGIES | ENPP2, BPGM, BMP6 | FDPS 1478/4885ANPEP 83/4885ERAP2 204/4885 |
| US-20020176818-A1 | High dose radionuclide complexes for bone marrow suppression | CSF3R, ACP1, BPGM | FDPS 1763/4885ANPEP 78/4885ERAP2 361/4885 |
| US-20060251578-A1 | Structurally distinct radionuclide complexes of multinitrogen heterocycles having phosphonic acid groups that target bone, and thus, are useful as imaging and therapeutic agents (e.g., for bone marrow suppression, cancer, bone pain) | PHOSPHO1, SNRPA1, NPM1 | FDPS 2837/4885ANPEP 301/4885ERAP2 2510/4885 |
| US-20070053833-A1 | High dose radionuclide complexes for bone marrow suppression | CSF3R, ACP1, BPGM | FDPS 1763/4885ANPEP 78/4885ERAP2 361/4885 |
| US-20090136419-A1 | HIGH DOSE RADIONUCLIDE COMPLEXES FOR BONE MARROW TREATMENT | CSF3R, ACP1, MPL | FDPS 1884/4885ANPEP 60/4885ERAP2 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.